open access

Vol 74, No 1 (2023)
Original paper
Submitted: 2022-02-24
Accepted: 2022-03-10
Published online: 2022-12-20
Get Citation

Overexpression of Wnt7b antagonizes the inhibitory effect of dexamethasone on osteoblastogenesis of ST2 cells

Yuan Gu1, Yongquan Gao1, Zhanghuan Yang23, Jiangdong Ni1, Guangxu He1
·
Pubmed: 36704983
·
Endokrynol Pol 2023;74(1):83-88.
Affiliations
  1. Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China
  2. Xiangya Cancer Centre, Xiangya Hospital, Central South University, Changsha, China
  3. Key Laboratory of Molecular Radiation Oncology Hunan Province, Changsha, China

open access

Vol 74, No 1 (2023)
Original Paper
Submitted: 2022-02-24
Accepted: 2022-03-10
Published online: 2022-12-20

Abstract

Introduction: It is well established that glucocorticoid-induced osteoporosis is highly associated with preosteoblast differentiation and function. This study is based on the premise that Wnt7b can promote bone formation through Wnt signalling pathway because it can stimulate preosteoblast differentiation and increase its activity. However, it is unknown whether Wnt7b can rescue the inhibited osteoblast differentiation and function caused by exogenous glucocorticoid.

Material and methods: In this study we used Wnt7b overexpression ST2 cells to explore whether Wnt7bcan rescue the inhibited osteoblast differentiation and function, which can provide strong proof to investigate a new drug for curing the glucocorticoid induced osteoporosis.

Results/Conclusion: We found that Wnt7b can rescue the suppressed osteoblast differentiation and function without cell viability caused by dexamethasone.

Abstract

Introduction: It is well established that glucocorticoid-induced osteoporosis is highly associated with preosteoblast differentiation and function. This study is based on the premise that Wnt7b can promote bone formation through Wnt signalling pathway because it can stimulate preosteoblast differentiation and increase its activity. However, it is unknown whether Wnt7b can rescue the inhibited osteoblast differentiation and function caused by exogenous glucocorticoid.

Material and methods: In this study we used Wnt7b overexpression ST2 cells to explore whether Wnt7bcan rescue the inhibited osteoblast differentiation and function, which can provide strong proof to investigate a new drug for curing the glucocorticoid induced osteoporosis.

Results/Conclusion: We found that Wnt7b can rescue the suppressed osteoblast differentiation and function without cell viability caused by dexamethasone.

Get Citation

Keywords

Wnt7b; osteoblast; dexamethasone

About this article
Title

Overexpression of Wnt7b antagonizes the inhibitory effect of dexamethasone on osteoblastogenesis of ST2 cells

Journal

Endokrynologia Polska

Issue

Vol 74, No 1 (2023)

Article type

Original paper

Pages

83-88

Published online

2022-12-20

Page views

2806

Article views/downloads

375

DOI

10.5603/EP.a2022.0035

Pubmed

36704983

Bibliographic record

Endokrynol Pol 2023;74(1):83-88.

Keywords

Wnt7b
osteoblast
dexamethasone

Authors

Yuan Gu
Yongquan Gao
Zhanghuan Yang
Jiangdong Ni
Guangxu He

References (35)
  1. Lee P, Greenfield JR. What is the optimal bone-preserving strategy for patients with Addison's disease? Clin Endocrinol (Oxf). 2015; 83(2): 157–161.
  2. Weinstein RR. Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin North Am. 2012; 41(3): 595–611.
  3. Compston J. Glucocorticoid-induced osteoporosis: an update. Endocrine. 2018; 61(1): 7–16.
  4. Lane NE. Glucocorticoid-Induced Osteoporosis: New Insights into the Pathophysiology and Treatments. Curr Osteoporos Rep. 2019; 17(1): 1–7.
  5. Chotiyarnwong P, McCloskey EV. Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nat Rev Endocrinol. 2020; 16(8): 437–447.
  6. Güler-Yüksel M, Hoes J, Bultink I, et al. Glucocorticoids, Inflammation and Bone. Calcif Tis Int. 2018; 102(5): 592–606.
  7. Sambrook PN, Saag KG, Shane E, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007; 357(20): 2028–2039.
  8. Lerner UH, Ohlsson C. The WNT system: background and its role in bone. J Intern Med. 2015; 277(6): 630–649.
  9. Long F. Building strong bones: molecular regulation of the osteoblast lineage. Nat Rev Mol Cell Biol. 2011; 13(1): 27–38.
  10. Zhou H, Mak W, Zheng Y, et al. Osteoblasts directly control lineage commitment of mesenchymal progenitor cells through Wnt signaling. J Biol Chem. 2008; 283(4): 1936–1945.
  11. Cruciat CM, Niehrs C. Secreted and transmembrane wnt inhibitors and activators. Cold Spring Harb Perspect Biol. 2013; 5(3): a015081.
  12. Li X, Zhang Y, Kang H, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005; 280(20): 19883–7.
  13. Semenov MV, Tamai K, Brott BK. Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6. Curr Biol. 2001; 11(12): 951–61.
  14. Guañabens N, Gifre L, Peris P. The role of Wnt signaling and sclerostin in the pathogenesis of glucocorticoid-induced osteoporosis. Curr Osteoporos Rep. 2014; 12(1): 90–97.
  15. Ohnaka K, Taniguchi H, Kawate H, et al. Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: novel mechanism of glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun. 2004; 318(1): 259–264.
  16. Butler J, Queally J, Devitt B, et al. Silencing Dkk1 expression rescues dexamethasone-induced suppression of primary human osteoblast differentiation. BMC Musculoskelet Disord. 2010; 11(1).
  17. Colditz J, Thiele S, Baschant U, et al. Osteogenic Dkk1 Mediates Glucocorticoid-Induced but Not Arthritis-Induced Bone Loss. J Bone Miner Res. 2019; 34(7): 1314–1323.
  18. Sato AY, Cregor M, Delgado-Calle J, et al. Protection From Glucocorticoid-Induced Osteoporosis by Anti-Catabolic Signaling in the Absence of Sost/Sclerostin. J Bone Miner Res. 2016; 31(10): 1791–1802.
  19. Yao W, Dai W, Jiang L, et al. Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength. Osteoporos Int. 2016; 27(1): 283–294.
  20. Saag KG, Petersen J, Brandi ML, et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med. 2017; 377(15): 1417–1427.
  21. Fixen Cy, Tunoa J. Romosozumab: a Review of Efficacy, Safety, and Cardiovascular Risk. Curr Osteoporos Rep. 2021; 19(1): 15–22.
  22. Hu H, Hilton MJ, Tu X, et al. Sequential roles of Hedgehog and Wnt signaling in osteoblast development. Development. 2005; 132(1): 49–60.
  23. Tu X, Joeng KS, Nakayama KI, et al. Noncanonical Wnt signaling through G protein-linked PKCdelta activation promotes bone formation. Dev Cell. 2007; 12(1): 113–27.
  24. Mak W, Shao X, Dunstan CR, et al. Biphasic glucocorticoid-dependent regulation of Wnt expression and its inhibitors in mature osteoblastic cells. Calcif Tissue Int. 2009; 85(6): 538–545.
  25. Zhang L, Zhang L, You H, et al. Inhibition of osteoclastogenesis by histone deacetylase inhibitor Quisinostat protects mice against titanium particle-induced bone loss. Eur J Pharmacol. 2021; 904: 174176.
  26. Yang Y, Liu Q, Zhang L, et al. A modified tape transfer approach for rapidly preparing high-quality cryosections of undecalcified adult rodent bones. J Orthop Translat. 2021; 26: 92–100.
  27. Li X, Liu P, Liu W, et al. Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation. Nat Genet. 2005; 37(9): 945–952.
  28. Li X, Zhang Y, Kang H. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005; 280(20): 19883–19887.
  29. Yu F, Wu F, Li F, et al. Wnt7b-induced Sox11 functions enhance self-renewal and osteogenic commitment of bone marrow mesenchymal stem cells. Stem Cells. 2020; 38(8): 1020–1033.
  30. Shen L, Zhou S, Glowacki J. Effects of age and gender on WNT gene expression in human bone marrow stromal cells. J Cell Biochem. 2009; 106(2): 337–343.
  31. Holguin N, Brodt MD, Silva MJ. Activation of Wnt Signaling by Mechanical Loading Is Impaired in the Bone of Old Mice. J Bone Miner Res. 2016; 31(12): 2215–2226.
  32. Song D, He G, Song F, et al. Inducible expression of Wnt7b promotes bone formation in aged mice and enhances fracture healing. Bone Res. 2020; 8: 4.
  33. Chen J, Tu X, Esen E, et al. WNT7B Promotes Bone Formation in part through mTORC1. PLoS Genetics. 2014; 10(1): e1004145.
  34. Chen H, Ji X, Lee WC, et al. Increased glycolysis mediates Wnt7b-induced bone formation. FASEB J. 2019; 33(7): 7810–7821.
  35. Chen H, Song F, Long F. WNT7B overexpression rescues bone loss caused by glucocorticoids in mice. FASEB J. 2021; 25(7): e21683.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl